Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 43Rectal Neoplasms 12Colonic Neoplasms 12Neoplasm Metastasis 6Stomach Neoplasms 5Pancreatic Neoplasms 5Gallbladder Neoplasms 3Colorectal Cancer Metastatic 3Cholangiocarcinoma 3Neutropenia 2Neoplasms 2Bile Duct Neoplasms 2Adenocarcinoma 2mCRC 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor 1Recurrence 1Pretreated Metastatic Colorectal Cancer 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Nasopharyngeal Carcinoma 1Microsatellite-stable Colorectal Cancer 1Metastatic Gastric Adenocarcinoma 1High-grade Extra Pulmonary Neuroendocrine Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Gastric Adenocarcinoma 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1pembrolizumab 1Trifluridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastric and Gastroesophageal Junction Adenocarcinoma × trifluridine tipiracil drug combination × Clear all
NCT05508737 2025-07-11

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

Yonsei University

Phase 1/2 Active not recruiting
75 enrolled
Gastrointestinal

Gastric and Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡